Impact of increased adiposity on extended aromatase inhibitor treatment in postmenopausal patients with estrogen receptor positive (ER plus ) breast cancer: a retrospective analysis of the SOLE trial

被引：0
|
作者：
Isnaldi, Edoardo
Richard, Francois
Marano, Giuseppe
Boracchi, Patrizia
Maetens, Marion
Floris, Giuseppe
Jerusalem, Guy
Gombos, Andrea
Thompson, Alastair M.
Stefan, Erika Hitre
Colleoni, Marco
Dell'Orto, Patrizia
Kammler, Roswitha
Neven, Patrick
Viale, Giuseppe
Regan, Meredith
Biganzoli, Elia
Desmedt, Christine
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P3-05-28
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-05-28
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Whole genome comparisons of pre- and post-aromatase inhibitor treatment in estrogen receptor positive breast cancer
    Ellis, Matthew J.
    Lie, Ding
    Shen, Dong
    Luo, Jingqin
    Suman, Vera J.
    Wallis, John W.
    Van Tine, Brian A.
    Hoog, Jeremy
    Crowder, Robert J.
    Snider, Jacqueline E.
    Ballman, Karla
    Chen, Ken
    Koboldt, Daniel C.
    Schierding, William S.
    McMichael, Joshua F.
    Miller, Christopher A.
    Kandoth, Cyriac
    Lu, Charles
    Harris, Christopher C.
    McLellan, Michael D.
    Wendl, Michael C.
    DeSchryver, Katherine
    Allred, D. Craig
    Esserman, Laura
    Unzeitig, Gary
    Margenthaler, Julie
    Babiera, G. V.
    Marcom, P. Kelly
    Guenther, J. M.
    Leitch, Marilyn
    Hunt, Kelly
    Olson, John
    Tao, Yu
    Fulton, Lucinda L.
    Fulton, Robert S.
    Harrison, Michelle
    Oberkfell, Ben
    Du, Feiyu
    Demeter, Ryan
    Griffith, Malachi
    Vickery, Tammi L.
    McDonald, Sandra A.
    Watson, Mark
    Dooling, David J.
    Ota, David
    Chang, Li-Wei
    Bose, Ron
    Ley, Timothy J.
    Wilson, Richard K.
    Mardis, Elaine R.
    CANCER RESEARCH, 2012, 72
  • [22] Overexpression of P53 is prognostic for aromatase inhibitor (AI) resistance in early stage postmenopausal patients with ER-positive breast cancer: A retrospective analysis in AI-treated patients
    Jia, X. Q.
    Hong, Q.
    Cheng, J. Y.
    Li, J. W.
    Wang, Y. J.
    Mo, M.
    Shao, Z. M.
    Shen, Z. Z.
    Liu, G. Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S440 - S440
  • [23] Development of cardiac events in postmenopausal breast cancer patients treated with Aromatase inhibitor (AI) and Selective estrogen receptor modulator (SERM).
    Parajuli, Priyanka
    Regmi, Manjari Rani
    Maini, Ruby
    Garcia, Odalys Estefania Lara
    Tandan, Nitin
    Mirihagalle, Noupama
    Cheema, Asad
    Abedrabo, Sabree
    Niaz, Zurain
    Koester, Cameron
    Sahib, Hamsa
    Bhandari, Bishal
    Johnson, Alexander
    Ibrahim, Abdisamad M.
    Delfino, Kristin
    Robinson, Kathy
    Desai, Meghna R.
    Kulkarni, Abhishek
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] VALIDATION OF PRO_10, A MULTIGENE PROGNOSTIC SIGNATURE, IN PATIENTS (PTS) WITH EARLY, ESTROGEN RECEPTOR POSITIVE (ER plus ) POSTMENOPAUSAL BREAST CANCER (BC)
    Moor, A. E.
    Guevara, C.
    Altermatt, H. J.
    Jaggi, R.
    Aebi, S.
    ANNALS OF ONCOLOGY, 2010, 21 : 80 - 80
  • [25] Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER plus ) primary breast cancer and paired recurrence
    Dieci, Maria Vittoria
    Barbieri, Elena
    Goubar, Aicha
    Andre, Fabrice
    Omarini, Claudia
    Bettelli, Stefania Raffaella
    Piacentini, Federico
    Ficarra, Guido
    Conte, Pier Franco
    Guameri, Valentina
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis
    Chen, Juan
    Zhang, Xiaohui
    Lu, Yan
    Zhang, Ting
    Ouyang, Zhaolian
    Sun, Qiang
    BREAST CANCER, 2021, 28 (03) : 630 - 643
  • [27] Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis
    Juan Chen
    Xiaohui Zhang
    Yan Lu
    Ting Zhang
    Zhaolian Ouyang
    Qiang Sun
    Breast Cancer, 2021, 28 : 630 - 643
  • [28] Randomized Phase II Study of Fulvestrant Versus Fulvestrant Plus Bortezomib in Postmenopausal Women with Estrogen Receptor (ER) Positive, Aromatase-Inhibitor (Al) Resistant Metastatic Breast Cancer (MBC): New York Cancer Consortium Trial P8457.
    Adelson, K. B.
    Raptis, G.
    Sparano, J.
    Germain, D.
    CANCER RESEARCH, 2011, 71
  • [29] Progesterone receptor levels are associated with time to aromatase inhibitor treatment failure in estrogen receptor-positive advanced breast cancer.
    Cristofanilli, M.
    De Giorgi, U.
    Rohren, E.
    Ueno, N. T.
    Miller, C.
    Doyle, G., V
    Jackson, S.
    Andreopoulou, E.
    Handy, B. C.
    Reuben, J. M.
    Hortobagyi, G. N.
    Macapinlac, H. A.
    Fritsche, H. A.
    Valero, V.
    CANCER RESEARCH, 2009, 69 (02) : 362S - 362S
  • [30] Mathematical modeling identifies optimum palbociclib dosing schedules for the treatment of estrogen receptor-positive (ER plus ) breast cancer patients
    Stein, Shayna
    Nardone, Agostina
    Liu, Weihan
    Cohen, Gabriella
    Guarducci, Cristina
    Brown, Myles
    Jeselsohn, Rinath
    Michor, Franziska
    CANCER RESEARCH, 2020, 80 (11) : 63 - 63
12345